Houston, Texas--(Newsfile Corp. - March 11, 2020) - There's a global march toward psychedelics for medicinal benefits.
While research has been off limits for decades, that's quickly changing - and fast.
In recent years, the US FDA granted Breakthrough Therapy designation for Compass Pathways' psilocybin treatment for depression. Denver, Oakland, and Santa Cruz just decriminalized the use of magic mushrooms. Chicago city leaders just passed a resolution supporting scientific and medicinal research, with a goal of decriminalization.
All on evidence the drug can improve obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression, anxiety, and even smoking.
Even more impressive, a study in the Journal of Psychopharmacology found that a single mushroom-based treatment can help improve the lives of cancer patients' quality of life for nearly five years. This study builds on a 2016 study that provided treatments to 29 people suffering with life-threatening cancer, and were also diagnosed with depression or anxiety.
In addition, "Theoretically, psilocybin helps "loosen" the deeply-rooted patterns of thinking and behavior behind many of these mental disorders, according to King's College London, as highlighted by CNN. It could 'relax' the parts of our brain that control these behaviors, thus allowing old patterns to change or fade. Patients who have received psilocybin have described coming down from the high with "new insights" and changed perspectives on their difficulties."
Before long, big pharmaceutical companies will jump on the bandwagon.
At the moment, venture capitalists are jumping on the opportunity.
"I view the next five years as an absolutely golden window. There's an opportunity to use relatively small amounts of money to have billions of dollars of impact and to affect millions of lives," says angel investor Tim Ferriss, who has poured money into advancing research on the mushroom market, as quoted by Forbes. "There just aren't that many opportunities that are so dramatically obvious."
In addition, a good chunk of venture capital money has been raised to date from firms such as Field Trip Ventures, Numinus, and Tabula Rasa. Compass Pathways, raised $55 million from Thiel Capital and Galaxy Ventures's Michael Novogratz, as well says Fortune.
Before long, big pharmaceutical companies could soon jump on the opportunity, too.
After all, if psychedelics, like mushrooms continue to prove effective in the treatment of depression, ADHD, anxiety, addiction, and neurological disorders, pharmaceutical companies could jump on the opportunity, as well. Traditional pharmaceutical companies already earn billions to manufacture other drugs for such ailments.
If psychedelics can prove themselves effective, it'll open another billion-dollar opportunity.
One of the top companies to watch is Yield Growth, which has made substantial moves into psilocybin mushrooms.
Just recently, Yield Growth developed Ayurvedic mushroom coffees and Ayurvedic mushroom botanical shots for smoothies. In fact, its Ayurvedic coffees and botanical shots are planned for launch in early summer of 2020 and contain immune-boosting medicinal mushrooms: reishi, chaga, lion's mane and turkey tail.
"These formulations provide powerful brain and immune-boosting benefits thanks to their powerful antioxidant and nutrient-rich formulas," said Penny White, CEO of The Yield Growth Corp. "Along with their powerful health profile, these products are made with fair-trade, organic ingredients."
Chaga mushrooms have been used for centuries in Siberia and Asia as medicine to reduce inflammation, boost immunity and improve overall health. Chaga also has the ability to lower high blood sugar and combat abnormal and mutagenic cell growth.
Turkey Tail also contains a community of powerful antioxidants and other compounds that may help boost your immune system and may even fight certain cancers. Some scientific studies have also shown that Turkey Tail may also improve gut bacteria balance.
Reishi is one of the most popular medicinal mushrooms and is known to be used to assist in weight loss, boost immunity and fight certain cancer cells. What makes it unique though are its calming properties thanks to a compound called triterpene that it contains. This can help to promote healing, sharpen focus, alleviate anxiety, ease depression, and encourage better sleep.
Lion's Mane is also packed with antioxidants and also strengthens the immune system, but it also has other unique benefits that foster mental clarity and brain health. For example, it aids in the production of the bioprotein nerve growth factor (NFG) and myelin, which acts as "insulation" around nerve fibers and helps to fight the onset of neurological diseases such as Alzheimer's and multiple sclerosis.
However, that's just part of Yield Growth's story.
Flourish Mushroom Labs Inc. also announced it acquired technology rights from its parent company The Yield Growth Corp. and filed a U.S. provisional patent for the invention of a method of manufacture for a mushroom extract that may be used in a variety of therapeutic and pharmaceutical formulations.
The patent application covers the invention of a unique mushroom extract which may have unique medicinal properties, as well as a method of manufacturing the extract from mushrooms including Psilocybe mexicana, and formulations and emulsions containing the mushroom extract. The mushroom extract may be in the form of an aqueous solution, or it may be a freeze or spray dried powder.
"Our proprietary extraction technology was initially invented to extract compounds from the root of the cannabis plant to manufacture hemp root oil, which we use in a number of our products, including our Urban Juve skincare line," said Penny White, CEO of The Yield Growth Corp. and Flourish Mushroom Labs. "There is now also great interest in using this technology for medicinal mushrooms and psychedelic mushrooms when and where they are legal."
For more information, visit the company's website at https://yieldgrowth.com.
MarijuanaStox.com is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. MarijuanaStox.com is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/53352